548,850 Shares in Immunome, Inc. $IMNM Bought by Nan Fung Trinity HK Ltd.

Nan Fung Trinity HK Ltd. purchased a new stake in shares of Immunome, Inc. (NASDAQ:IMNM) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 548,850 shares of the company’s stock, valued at approximately $5,104,000.

A number of other large investors also recently modified their holdings of IMNM. Teacher Retirement System of Texas lifted its stake in shares of Immunome by 6.8% in the 2nd quarter. Teacher Retirement System of Texas now owns 18,548 shares of the company’s stock valued at $172,000 after purchasing an additional 1,188 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its holdings in Immunome by 3.2% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 53,187 shares of the company’s stock valued at $470,000 after buying an additional 1,643 shares during the period. Invesco Ltd. lifted its position in Immunome by 6.4% during the first quarter. Invesco Ltd. now owns 28,379 shares of the company’s stock valued at $191,000 after buying an additional 1,718 shares in the last quarter. Voya Investment Management LLC grew its stake in Immunome by 21.2% during the first quarter. Voya Investment Management LLC now owns 18,905 shares of the company’s stock worth $127,000 after buying an additional 3,305 shares during the period. Finally, Los Angeles Capital Management LLC increased its position in shares of Immunome by 16.8% in the second quarter. Los Angeles Capital Management LLC now owns 41,857 shares of the company’s stock worth $389,000 after acquiring an additional 6,009 shares in the last quarter. 44.58% of the stock is currently owned by hedge funds and other institutional investors.

Immunome Stock Performance

Shares of IMNM opened at $17.52 on Wednesday. Immunome, Inc. has a one year low of $5.15 and a one year high of $17.87. The stock has a 50-day moving average price of $13.13 and a 200 day moving average price of $10.63. The company has a market capitalization of $1.61 billion, a P/E ratio of -5.94 and a beta of 1.96.

Immunome (NASDAQ:IMNM) last released its earnings results on Thursday, November 6th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.08). Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.50%. As a group, equities research analysts forecast that Immunome, Inc. will post -2.21 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. Evercore ISI began coverage on shares of Immunome in a report on Friday, August 22nd. They set an “outperform” rating and a $18.00 target price on the stock. Wedbush reissued an “outperform” rating and issued a $21.00 price objective on shares of Immunome in a research report on Friday, November 7th. Guggenheim reaffirmed a “buy” rating and issued a $25.00 target price on shares of Immunome in a research report on Monday, August 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunome in a research note on Wednesday, October 8th. Finally, The Goldman Sachs Group assumed coverage on Immunome in a report on Monday, September 22nd. They issued a “buy” rating and a $26.00 price target for the company. Ten research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $23.20.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.